Sugi Predict

Sugi Predict / Compounds / SCHEMBL604267

SCHEMBL604267

SCHEMBL604267

CCCC(=O)OCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C

nearest known ligand 0.80

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 3/20 0.80
▸ AR P10275 2/20 0.80
▸ CHRM1 P11229 2/20 0.80
▸ NR3C2 P08235 7/20 0.77
▸ NR3C1 P04150 2/20 0.77
▸ HIF1A Q16665 9/20 0.71
▸ KMT2A Q03164 1/20 0.71
▸ SMN1; SMN2 Q16637 2/20 0.68
▸ POLB P06746 1/20 0.68
▸ GAA P10253 1/20 0.68
▸ MAPT P10636 1/20 0.68
▸ LMNA P02545 2/20 0.66
▸ SERPINA6 P08185 1/20 0.66
▸ PMP22 Q01453 1/20 0.65
▸ TSHR P16473 1/20 0.65
▸ NFKB1 P19838 1/20 0.65
▸ CYP3A4 P08684 1/20 0.60
▸ CYP2C19 P33261 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17219849 1.00 PGR (0.80) PGRARCHRM1NR3C2NR3C1
SCHEMBL605474 0.95 NR3C2 (0.85) PGRARCHRM1NR3C2NR3C1
SCHEMBL122187 0.94 PGR (0.85) PGRARCHRM1NR3C2NR3C1
SCHEMBL4285507 0.94 PGR (0.88) PGRARCHRM1NR3C2NR3C1
SCHEMBL4290159 0.94 PGR (0.85) PGRARCHRM1NR3C2NR3C1
SCHEMBL4285504 0.94 PGR (0.88) PGRARCHRM1NR3C2NR3C1
SCHEMBL11430451 0.93 NR3C2 (0.76) PGRARCHRM1NR3C2NR3C1
SCHEMBL11442370 0.93 NR3C2 (0.76) PGRARCHRM1NR3C2NR3C1
Hydrocortisone Probutate SCHEMBL4280673 0.92 PGR (0.82) PGRARCHRM1NR3C2NR3C1
Hydrocortisone Probutate SCHEMBL4778 0.92 PGR (0.82) PGRARCHRM1NR3C2NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106572970-B Novel gel for topical administration of non-steroidal anti-inflammatory drugs for relief of musculoskeletal pain and method of making same 詹姆斯·布兰查德 2021-04-06 — — CN claimed
WO-2015191402-A1 NOVEL GEL FOR TOPICAL DELIVERY OF NSAIDS TO PROVIDE RELIEF OF MUSCULOSKELETAL PAIN AND METHODS FOR ITS PREPARATION BLANCHARD JAMES (US) 2015-12-17 — — WO claimed
US-9012402-B1 Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation BLANCHARD JAMES (US) 2015-04-21 — — US claimed
US-20240209076-A1 USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF KODIAK SCIENCES INC. 2024-06-27 — — US disclosed
US-20240189237-A1 FORMULATION AND METHOD FOR TREATMENT OF URINARY SYSTEM DISORDERS WATERSHED MEDICAL INC (US) 2024-06-13 — — US disclosed
US-20240156720-A1 COMPOSITIONS FOR BLOOD STORAGE AND TRANSFUSIONS ALBERT EINSTEIN COLLEGE OF MEDICINE 2024-05-16 — — US disclosed
US-20240139133-A1 TOPICAL NAPROXEN FORMULATIONS AND THEIR USE SMARTECH TOPICAL, INC. (US) 2024-05-02 — — US disclosed
EP-4333826-A1 TOPICAL NAPROXEN FORMULATIONS AND THEIR USE Smartech Topical, Inc. (US) 2024-03-13 — — EP disclosed
US-20240050362-A1 TRANSDERMAL DELIVERY FORMULATIONS ALBERT EINSTEIN COLLEGE OF MEDICINE 2024-02-15 — — US disclosed
EP-4319724-A1 FORMULATION AND METHOD FOR TREATMENT OF URINARY SYSTEM DISORDERS Watershed Medical, Inc. (US) 2024-02-14 — — EP disclosed
EP-4313007-A1 TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT Lyfe CHNG, LLC (US) 2024-02-07 — — EP disclosed
US-20030104041-A1 Transdermal and topical administration of drugs using basic permeation enhancers DERMATRENDS, INC. 2003-06-05 — — US disclosed
US-20030091630-A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data ASSERTIO THERAPEUTICS, INC. 2003-05-15 — — US disclosed
WO-2003035029-A1 FORMULATION OF AN ERODIBLE, GASTRIC RETENTIVE ORAL DOSAGE FORM USING IN VITRO DISINTEGRATION TEST DATA DEPOMED, INC. (US) 2003-05-01 — — WO disclosed
WO-2003035041-A1 GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG RELEASE IN THE LOWER GASTROINTESTINAL TRACT DEPOMED, INC. (US) 2003-05-01 — — WO disclosed
EP-1239845-A2 HYDROXIDE-RELEASING AGENTS AS SKIN PERMEATION ENHANCERS Dermatrends, Inc. (US) 2002-09-18 — — EP disclosed
US-20020034554-A1 Dual enhancer composition for topical and transdermal drug delivery TECHNOLOGY RECOVERY SYSTEMS, LLC 2002-03-21 — — US disclosed
US-20010051166-A1 Hydroxide-releasing agents as skin permeation enhancers TECHNOLOGY RECOVERY SYSTEMS, LLC 2001-12-13 — — US disclosed
US-20010038861-A1 Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers TRS II, LLC 2001-11-08 — — US disclosed
WO-2001043775-A2 HYDROXIDE-RELEASING AGENTS AS SKIN PERMEATION ENHANCERS DERMATRENDS, INC. (US) 2001-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020034554-A1 Dual enhancer composition for topical and transdermal drug delivery LIPA, FAAH2, MGLL PGR 309/4885AR 491/4885CHRM1 2913/4885
US-20240209076-A1 USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF IL6, FLT4, TEK PGR 2333/4885AR 4016/4885CHRM1 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.